European urology最新文献

{"title":"Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial","authors":"David C. Chen, Abdullah Al-Khanaty, David Hennes, Marlon L. Perera, Nathan Lawrentschuk, Declan G. Murphy","doi":"10.1016/j.eururo.2025.04.024","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.04.024","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"55 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143931026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression” [Eur. Urol. 76(2) (2019) 157–166]","authors":"Yinan Li, Ning Xie, Ruiqi Chen, Ahn R Lee, Jessica Lovnicki, Emma A Morrison, Ladan Fazli, Qingfu Zhang, Catherine A Musselman, Yuzhuo Wang, Jiaoti Huang, Martin E Gleave, Colin Collins, Xuesen Dong","doi":"10.1016/j.eururo.2025.04.022","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.04.022","url":null,"abstract":"The authors regret, There was an error in <strong>Fig. 5</strong>C where the p38 Western blot image was inadvertently assembled. A corrected version of the Western blot is included below. The incorrectly assembled figure does not change any scientific conclusions of the study. The caption remains correct with the replacement images.<span><figure><span><img alt=\"\" height=\"300\" src=\"https://ars.els-cdn.com/content/image/1-s2.0-S0302283825002611-fx1.jpg\"/><ol><li><span><span>Download: <span>Download high-res image (164KB)</span></span></span></li><li><span><span>Download: <span>Download full-size image</span></span></span></li></ol></span></figure></span>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"3 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease","authors":"Andrea Salonia, Paolo Capogrosso, Luca Boeri, Andrea Cocci, Giovanni Corona, Marij Dinkelman-Smit, Marco Falcone, Christian Fuglesang Jensen, Murat Gül, Arif Kalkanli, Ates Kadioğlu, Juan I. Martinez-Salamanca, L. Afonso Morgado, Giorgio I. Russo, Ege Can Serefoğlu, Paolo Verze, Suks Minhas","doi":"10.1016/j.eururo.2025.04.010","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.04.010","url":null,"abstract":"<h3>Objective</h3>The objective of this study is to present a summary of the updated 2025 European Association of Urology (EAU) guidelines on sexual and reproductive health (SRH), focusing on hypogonadism, erectile dysfunction (ED), premature ejaculation (PE), and Peyronie’s disease (PD), providing practical recommendations on the clinical workup, with a focus on diagnosis, treatment, and follow-up.<h3>Evidence acquisition</h3>The panel conducted an updated systematic review of new research published in 2021–2024 in Medline, EMBASE, and Cochrane Libraries. The guidelines’ recommendations focused on key clinical decisions that would impact patient care most. Each recommendation’s strength was evaluated based on three factors: the trade-offs between benefits and drawbacks of different treatment approaches, the quality and reliability of the available evidence, and the diverse preferences and values of patients.<h3>Key findings</h3>Along with a detailed basic and advanced diagnostic approach for every condition, key recommendations emphasise the importance of appropriate indications and subsequent follow-up for testosterone therapy in patients with late-onset hypogonadism (LOH), a clinical condition in the ageing male combining low levels of circulating testosterone and specific symptoms associated with impaired hormone production and/or action. The decision-making algorithm for treating ED—defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance—aims to support personalised treatment tailored to individual patients, according to the invasiveness, tolerability, and effectiveness of the different therapeutic options and patients’ expectations. Hence, patients should be fully counselled with respect to all available treatment modalities. The EAU guidelines adopted the definition of PE, which has been developed by the International Society for Sexual Medicine<em>.</em> After the subtype of PE has been defined, patient’s expectations should be discussed thoroughly, and pharmacotherapy must be considered as the first-line treatment for patients with lifelong PE, whereas treating the underlying cause must be the initial goal for patients with acquired PE. An accurate baseline assessment of patients with PD should differentiate between acute and stable phases of the disorder. Surgical treatment for PD should be offered to patients having a penile deformity with a negative impact on sexual function: patients with concomitant ED should be offered penile prosthesis implantation.<h3>Conclusions and clinical implications</h3>This overview of the 2025 EAU SRH guidelines offers valuable insights into the diagnosis, treatment, and follow-up of LOH, ED, PE, and PD.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"20 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, et al. Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol 2024;42:4095–102","authors":"Paolo Zaurito, Marco Moschini, Alberto Briganti, Francesco Montorsi","doi":"10.1016/j.eururo.2025.03.024","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.024","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"27 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vesical Mucosal Graft for the Treatment of Ureteral Strictures with a Total Robot-assisted Approach","authors":"Ivano Morra, Giovanni Busacca, Paola Irene Ornaghi, Roberta Aimar, Filippo Poletti, Luciano Ola, Juliette Meziere, Bianca Sabrina Ribolzi, Ettore Dalmasso","doi":"10.1016/j.eururo.2025.04.016","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.04.016","url":null,"abstract":"<h3>Background and objective</h3>Ureteral strictures can be iatrogenic and caused by stones, radiation, autoimmune diseases, and trauma. Laparoscopic or robot-assisted ureteroplasty (RAUP) with grafts for short ureteral strictures has been described in several studies. Our objective was to show the efficacy and safety of vesical mucosa grafts (VMGs) for treatment of ureteral strictures via RAUP.<h3>Methods</h3>We conducted a single-center retrospective study to evaluate the role of VMGs in the treatment of iatrogenic ureteral strictures in a cohort of 14 patients who underwent RAUP. Descriptive analyses of clinical and demographic data, including stricture length, operative time, hospitalization, complications, and follow-up, were performed. All patients underwent RAUP using VMGs with a da Vinci Xi robotic system.<h3>Key findings and limitations</h3>Mean stricture length in the cohort was 4.07 cm (range 3–6). The mean operative time was 141 min (range 110–180) and the mean hospital stay was 6.3 d (range 5–10). No Clavien-Dindo grade &gt;2 complications were observed. No stenosis recurrence had occurred at 21.3 mo. Limitations include the small sample size and short follow-up.<h3>Conclusions and clinical implications</h3>Our study shows that RAUP with VMGs may represent a valid approach for the treatment of ureteral strictures of up to 6 cm in length.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"37 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143905702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Thomas van Doeveren, Sebastiaan Remmers, Egbert R. Boevé, et al. Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.12.006","authors":"Jianjun Ye, Qiang Wei, Yige Bao","doi":"10.1016/j.eururo.2025.03.026","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.026","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"58 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Richard J. Bryant, Ioana R. Marian, Roxanne Williams, et al. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. Lancet Oncol. In press. https://doi.org/10.1016/s1470-2045(25)00100-7","authors":"Alessandro Uleri, Michael Baboudjian, Guillaume Ploussard","doi":"10.1016/j.eururo.2025.04.021","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.04.021","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"18 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Aram Lyu, Zenghua Fan, Matthew Clark, et al. Evolution of Myeloid-mediated Immunotherapy Resistance in Prostate Cancer. Nature 2025;637:1207–17","authors":"Yongfeng Lao, Xin Guan, Yanan Bai, Zhilong Dong","doi":"10.1016/j.eururo.2025.04.020","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.04.020","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"18 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Thomas van Doeveren, Sebastiaan Remmers, Egbert R. Boevé, et al. Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.12.006","authors":"Kamil Malshy, Jathin Bandari, Edward M. Messing","doi":"10.1016/j.eururo.2025.02.033","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.02.033","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"10 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study","authors":"Madeleine J. Karpinski, Kambiz Rahbar, Martin Bögemann, Laya Rahbar Nikoukar, Michael Schäfers, Sebastian Hoberück, Matthias Miederer, Tobias Hölscher, Sazan Rasul, Marcin Miszczyk, Francesco Lanfranchi, Matteo Bauckneht, Christian H. Pfob, Felix Kind, Karolien Goffin, Anika Hüsing, Claudia Kesch, Ken Herrmann, Martin Stuschke, Andrei Gafita, Wolfgang P. Fendler","doi":"10.1016/j.eururo.2025.04.017","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.04.017","url":null,"abstract":"<h3>Background and objective</h3>We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP1). Here, we develop an updated PPP2 risk score from a large international multicentre registry study.<h3>Methods</h3>We included 6128 prostate cancer patients who underwent PSMA-PET at 20 hospitals in Europe, USA, and Australia between 2013 and 2022. Investigator sites were split 2:1 into the development (4044 patients) and validation (2084 patients) cohorts. We created nomograms of version 2 (PPP2) based on Cox regression models with the least absolute shrinkage and selection operator penalty for overall survival (development cohort). Performance of both nomograms was measured using Harrell’s C-index and calibration plots and a head-to-head comparison with the National Comprehensive Cancer Network (NCCN) risk score by receiver operating characteristic curves (validation cohort).<h3>Key findings and limitations</h3>Predictors were distant metastases (extrapelvic nodal metastases [M1a], bone metastases [M1b], and visceral metastases [M1c]), PSMA expression score, and total lesion count (visual PPP2) or total tumour volume (quantitative PPP2). C-indices (95% confidence interval) in the validation cohort were 0.80 (0.78–0.82; visual) and 0.80 (0.79–0.82; quantitative), respectively. Accuracy of both the PPP2 nomograms was superior to the NCCN risk score (<em>n</em> = 1034, area under the curve 0.84 vs 0.76; <em>p</em> &lt; 0.001). The retrospective design represents a limitation of the study.<h3>Conclusions and clinical implications</h3>PPP nomograms were improved in an international multicentre study to predict accurately the 3- and 5-yr overall survival probabilities of prostate cancer. PPP2 yielded superior accuracy to the NCCN risk score. A free software tool has been created for PROMISE and PPP2 assessments (promise-pet.org).","PeriodicalId":12223,"journal":{"name":"European urology","volume":"5 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}